Stock Ratings / Health Care / BVS / insiders

DRTS (39) PRCT (40) AORT (41) TNDM (30) ⌘ Pro Terminal →

Bioventus Inc. (Class A) (BVS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$14.87 +1.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.88

Bioventus Inc. (Class A) (BVS) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.25B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BVS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Bioventus Inc. (Class A) (NASDAQ: BVS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $14.87 (+1.50% 1D, market cap $1.25B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BVS ranks #128 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BVS compare to DRTS and PRCT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), BVS carries a Roarable C (65/100 RQD), trailing P/E of 55.0x, gross margin of 68.3%, and ROIC of 10.4%. By comparison, DRTS (Alpha Tau Medical Ltd.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and PRCT (PROCEPT BioRobotics Corporation) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BVS?

▼

Per BVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001665988), Bioventus Inc. (Class A) generated $568.1M in revenue (-0.9% YoY), $22.7M in net income, and $72.1M in free cash flow against $683.6M in total assets and $279.0M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Priced at 55x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.88 (+0.08%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 12.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BVS)Realized 20D OHLCV Swing Band: ±8.4%

Deterministic 5-Pillar Attribution (65/100 Composite)

🔍 WHY BVS SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (23% of score)

20D Institutional Volume Accumulation (±8.4% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (22% of score)

Altman Z-Score 2.25 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$13.53-0.3% Next Q

Q2 (-2Q)

Grade C$13.49+9.1% Next Q

Q3 (-1Q)

Grade C+$14.72+1% Next Q

Current

Grade C$14.87+1.3% Hist 90D α

Trajectory: C (57) → C (65)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the BVS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, BVS faces multiple-compression risk if 55.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 55x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 65.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.71) or 200D SMA ($10.94) invalidates the momentum regime and cuts Target Base ($15.34) toward Bear Floor ($11.97).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BVS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BVS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 65%NO 35%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

BVS Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BVS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BVS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (BVS Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +46.21%⚡ TESTING RESISTANCE

2026-11-02O $14.65H $14.87L $14.65C $14.87VOL 444.9K

RES: $15.45SUP: $12.88SMA50: $13.71SMA200: $10.94

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BVS Butterfly Map → + Track BVS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

39.0%/yr Implied 5Y Growth

vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BVS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BVS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BVS)

Health Care Rank #128 of 1016 ⚔️ DRTS vs BVS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BVS vs. DRTS, PRCT, AORT, TNDM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bioventus Inc. (Class A) (BVS) ranks #128 by composite RQD confidence (65/100, grade C) and #332 by equity capitalization ($1.25B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BVS ACTIVE Bioventus Inc. (Class A)	C	65/100	55.0x	68.3%	10.4%	+1.50%	$1.25B	Benchmark Subject
DRTS Alpha Tau Medical Ltd.	D-	39/100	—	—	-35.0%	-0.90%	$1.22B	/drts-vs-bvs →
PRCT PROCEPT BioRobotics Corporation	D-	40/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-bvs →
AORT Artivion Inc.	D-	41/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	/aort-vs-bvs →
TNDM Tandem Diabetes Care Inc.	E	30/100	—	53.8%	-35.0%	+0.56%	$1.38B	/tndm-vs-bvs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001665988

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bioventus Inc. (Class A) (BVS) reported GAAP revenue of $568.1M (-0.9% vs. FY2024 revenue of $573.3M , and +10.9% cumulative change since FY2023) , GAAP net income of $22.7M, operating cash flow of $74.7M, and free cash flow of $72.1M (+90.8% YoY). On the balance sheet, BVS closed FY2025 with $683.6M in total assets against $279.0M in total debt (Altman Z-Score: 2.25, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$568.1M	$22.7M	$74.7M	$72.1M	$683.6M	$279.0M
FY2024 (FY)	2024-12-31	$573.3M	-$36.1M	$38.8M	$37.8M	$728.0M	$308.3M
FY2023 (FY)	2023-12-31	$512.3M	-$156.2M	$15.3M	$15.3M	—	—

3. BVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BVS compare to DRTS and PRCT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BVS?

Where is BVS trading relative to its 50-day, 200-day, and 52-week technical levels?

BVS last traded at $14.87 (+1.50% on volume of 444,933 shares), positioning the stock +8.46% above its 50-day simple moving average ($13.71) and +35.92% above its 200-day simple moving average ($10.94). Across its 52-week range of $6.47 to $15.89, BVS sits at the 89.2% percentile with a 14-day RSI of 57.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.4% ($13.62 to $16.12).

BVS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are BVS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BVS leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: BVS RQD Cockpit BVS 12M Forecast BVS Earnings & Move BVS Dividends & DRIP BVS Insiders & 13F BVS Whale Options BVS Profit Sankey BVS News & Why